NRx Pharmaceuticals Inc. shares were recently up 44% to $9.75 following updates about Zyesami, in development for treatment of Covid-19 patients with respiratory failure.
The company said a revised Investigational New Drug module was submitted to the U.S. Food and Drug Administration, containing documentation that confirmed Nephron Pharmaceuticals Inc. is prepared to supply Zyesami on a commercial scale.
Meanwhile, NRx was notified that a European auditor completed an inspection at a separate manufacturing facility with no adverse findings.
In July, the company received the exclusive worldwide right to develop and market the BriLife Covid-19 vaccine developed by the Israel Institute for Biological Research.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.